The use of polygenic risk scores in pre-implantation genetic testing: an unproven, unethical practice

F. Forzano*, O. Antonova, A. Clarke, G. de Wert, S. Hentze, Y. Jamshidi, Y. Moreau, M. Perola, I. Prokopenko, A. Read, A. Reymond, V. Stefansdottir, C. van El, M. Genuardi, Executive Committee of the European Society of Human Genetics, Public and Professional Policy Committee of the European Society of Human Genetics

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

10 Citations (Web of Science)

Abstract

Y Polygenic risk score analyses on embryos (PGT-P) are being marketed by some private testing companies to parents using in vitro fertilisation as being useful in selecting the embryos that carry the least risk of disease in later life. It appears that at least one child has been born after such a procedure. But the utility of a PRS in this respect is severely limited, and to date, no clinical research has been performed to assess its diagnostic effectiveness in embryos. Patients need to be properly informed on the limitations of this use of PRSs, and a societal debate, focused on what would be considered acceptable with regard to the selection of individual traits, should take place before any further implementation of the technique in this population.
Original languageEnglish
Pages (from-to)493-495
Number of pages3
JournalEuropean Journal of Human Genetics
Volume30
Issue number5
Early online date17 Dec 2021
DOIs
Publication statusPublished - May 2022

Cite this